Krystal Biotech Inc Unsponsored BDR's next confirmed earnings release is scheduled for March 1, 2027.
| Earnings Date | 3/1/2027 |
As of September 30, 2026, Krystal Biotech Inc Unsponsored BDR has 854.27M shares outstanding.
| Shares Outstanding | 854.27M |
As of September 30, 2026, Krystal Biotech Inc Unsponsored BDR maintains a current ratio of 7.89, meaning it holds 7.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.89 |
| Quick Ratio | 7.35 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 0.04 |
Over the twelve months ended September 30, 2026, Krystal Biotech Inc Unsponsored BDR posted a return on equity (ROE) of 17.50, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.12 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 15.93, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.38, useful for judging operating efficiency across full business cycles. The company generates approximately 8.26M in revenue per employee across its workforce of 295.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.61 indicates how many times Krystal Biotech Inc Unsponsored BDR sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 17.50 |
| Return on Assets (ROA) | 15.93 |
| Return on Invested Capital (ROIC) | 15.12 |
| Return on Capital Employed (ROCE) | 17.38 |
| Revenue Per Employee | 8.26M |
| Employee Count | 295.00 |
| Inventory Turnover | 0.61 |
Over the twelve months ended September 30, 2026, Krystal Biotech Inc Unsponsored BDR recorded 174.28M in income tax expense. That works out to an effective tax rate of 12.99, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.34B, leaving 1.17B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 174.28M |
| Effective Tax Rate | 12.99 |
Over the twelve months ended September 30, 2026, Krystal Biotech Inc Unsponsored BDR generated 2.44B in revenue and converted that into 1.17B in net income, yielding earnings per share of 1.32. EBITDA reached 1.21B, while operating income came in at 1.18B.
| Revenue | 2.44B |
| Gross Profit | 2.30B |
| Operating Income | 1.18B |
| Pretax Income | 1.34B |
| Net Income | 1.17B |
| EBITDA | 1.21B |
| EBIT | 1.18B |
| Earnings Per Share (EPS) | 1.32 |
As of September 30, 2026, Krystal Biotech Inc Unsponsored BDR holds 4.73B in cash and equivalents against 44.51M in total debt, resulting in a net debt position of -2.40B. Total book value stands at 7.44B, with working capital of 5.08B providing operational flexibility.
| Cash & Cash Equivalents | 4.73B |
| Total Debt | 44.51M |
| Net Debt | -2.40B |
| Equity (Book Value) | 7.44B |
| Book Value Per Share | 8.71 |
| Working Capital | 5.08B |
Krystal Biotech Inc Unsponsored BDR produced 1.68B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -71.77M in capital expenditures, free cash flow totaled 1.61B - equivalent to 1.90 per share.
| Operating Cash Flow | 1.68B |
| Capital Expenditures | -71.77M |
| Free Cash Flow | 1.61B |
| FCF Per Share | 1.90 |
Over the twelve months ended September 30, 2026, Krystal Biotech Inc Unsponsored BDR posted a gross margin of 94.28, reflecting its pricing power and cost economics. The operating margin of 48.41 and net profit margin of 47.91 provide insight into operational efficiency.
| Gross Margin | 94.28 |
| Operating Margin | 48.41 |
| Pretax Margin | 55.06 |
| Profit Margin | 47.91 |
| EBITDA Margin | 49.84 |